Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Average Recommendation of “Hold” from Brokerages

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has earned an average rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $52.33.

ALPN has been the topic of several research reports. Leerink Partnrs cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 11th. HC Wainwright cut shares of Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, April 11th. Morgan Stanley reiterated an “equal weight” rating and set a $65.00 price objective (up previously from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Guggenheim started coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a “buy” rating and a $55.00 price objective on the stock. Finally, SVB Leerink cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $42.00 to $65.00 in a research report on Friday, April 12th.

Institutional Trading of Alpine Immune Sciences

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Alpine Immune Sciences during the first quarter valued at $27,000. Allspring Global Investments Holdings LLC lifted its stake in Alpine Immune Sciences by 745.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,312 shares during the period. EntryPoint Capital LLC lifted its stake in Alpine Immune Sciences by 1,239.3% in the first quarter. EntryPoint Capital LLC now owns 1,433 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,326 shares during the period. AJOVista LLC purchased a new stake in Alpine Immune Sciences in the fourth quarter worth about $64,000. Finally, Barclays PLC lifted its stake in Alpine Immune Sciences by 44.3% in the third quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 2,801 shares during the period. 75.17% of the stock is owned by hedge funds and other institutional investors.

Alpine Immune Sciences Stock Performance

Shares of ALPN opened at $64.97 on Thursday. The company’s fifty day moving average is $54.29 and its 200 day moving average is $33.58. Alpine Immune Sciences has a fifty-two week low of $8.33 and a fifty-two week high of $65.00. The stock has a market capitalization of $4.46 billion, a PE ratio of -101.52 and a beta of 0.97.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 65.17% and a negative return on equity of 14.86%. The company had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. As a group, research analysts forecast that Alpine Immune Sciences will post -1.74 earnings per share for the current year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.